Literature DB >> 31038789

Echocardiographic assessment of pulmonary arterial stiffness in human immunodeficiency virus-infected patients.

Idris Bugra Cerik1, Murat Meric2, Okan Gulel2, Hatun Ozturk Cerik3, Metin Coksevim4, Korhan Soylu2, Aydin Deveci5, Mahmut Sahin2.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is one of the complications of human immunodeficiency virus (HIV) infection. Despite the emergence of effective therapies, pulmonary arterial hypertension is commonly seen, especially at advanced stages. At the time of diagnosis, a majority of patients are at New York Heart Association-Functional Class III or IV. Many of the current screening modalities are dependent on detecting a rise in pulmonary arterial pressure (PAP). However, high capacitance of the pulmonary circulation implies that early microcirculation loss is not accompanied by a change in resting PAP. Therefore, we aimed to demonstrate early changes in pulmonary vascular disease in HIV-infected patients with a new echocardiographic parameter, called as pulmonary arterial stiffness (PAS). METHODS AND
RESULTS: Thirty-six HIV-infected patients and 36 age- and sex-matched healthy control subjects were enrolled in this study. PAS was calculated echocardiographically by using maximal frequency shift and acceleration time of the pulmonary artery flow trace. There was no significant difference in diastolic functions, right ventricular diameters, systolic PAP, inferior vena cava widths, right atrial area, and tricuspid annular plane systolic excursion values between the two groups. However, PAS was calculated as 24.3 ± 6.4 Hz/msn in HIV-infected patients and 19.3 ± 3.1 Hz/msn in healthy control group (P < 0.001). Increase in PAS was correlated with duration of HIV infection (P < 0.05).
CONCLUSION: Our results suggest that HIV infection affects pulmonary vascular bed starting early onset of disease and this can be demonstrated by an easy-to-measure echocardiographic parameter.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  echocardiography; human immunodeficiency virus; pulmonary arterial stiffness; pulmonary hypertension

Mesh:

Year:  2019        PMID: 31038789     DOI: 10.1111/echo.14349

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  5 in total

1.  Screening strategies for pulmonary arterial hypertension.

Authors:  David G Kiely; Allan Lawrie; Marc Humbert
Journal:  Eur Heart J Suppl       Date:  2019-12-17       Impact factor: 1.803

2.  Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction.

Authors:  Sencer Çamcı; Emre Yılmaz
Journal:  Medicina (Kaunas)       Date:  2022-08-19       Impact factor: 2.948

3.  Assessment of Pulmonary Arterial Hemodynamic and Vascular Changes by Pulmonary Pulse Transit Time in Patients with Human Immunodeficiency Virus Infection.

Authors:  Mehmet Akif Erdol; Burak Acar; Ahmet Goktug Ertem; Mustafa Karanfil; Çağrı Yayla; Koray Demırtas; Pelin Aladağ; Meliha Çağla Sönmezer; Esra Kaya Kiliç; Çiğdem Ataman Hatipoğlu; Fatma Sebnem Erdinc; Necla Tulek; Adnan Burak Akcay
Journal:  J Cardiovasc Echogr       Date:  2021-05-21

4.  HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.

Authors:  Brandy E Wade; Kristi M Porter; Sharilyn Almodovar; Justin M Smith; Robert A Lopez-Astacio; Kaiser Bijli; Bum-Yong Kang; Sushma K Cribbs; David M Guidot; Deborah Molehin; Bryan K McNair; Laura Pumarejo-Gomez; Jaritza Perez Hernandez; Ethan A Salazar; Edgar G Martinez; Laurence Huang; Cari F Kessing; Edu B Suarez-Martinez; Kevin Pruitt; Priscilla Y Hsue; William R Tyor; Sonia C Flores; Roy L Sutliff
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

5.  Noninvasive Measurement of Time-Varying Arterial Wall Elastance Using a Single-Frequency Vibration Approach.

Authors:  Jia-Jung Wang; Shing-Hong Liu; Wei-Kung Tseng; Wenxi Chen
Journal:  Sensors (Basel)       Date:  2020-11-12       Impact factor: 3.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.